Maori v. Maori

2002 DNH 089
CourtDistrict Court, D. New Hampshire
DecidedMay 1, 2002
DocketCV-01-464-JD
StatusPublished
Cited by1 cases

This text of 2002 DNH 089 (Maori v. Maori) is published on Counsel Stack Legal Research, covering District Court, D. New Hampshire primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maori v. Maori, 2002 DNH 089 (D.N.H. 2002).

Opinion

Maori v. Maori CV-01-464-JD 05/01/02 UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE

Vincent J. Maori and Ecruichem Research Institute, Ltd.

v. Civil No. 01-464-JD Opinion No. 2002 DNH 089 James N. Maori and NTD Labs., Inc.

O R D E R

The plaintiffs, Vincent Macri and Equichem Research

Institute, Ltd., bring an action arising out of their failed

business relationship with the defendants, James Macri and NTD

Labs. The plaintiffs allege claims of misappropriation, unfair

competition, unjust enrichment, breach of contract, and copyright

infringement. The plaintiffs also seek injunctive relief. The

defendants move to dismiss the action, asserting that the court

lacks personal jurisdiction and that the plaintiffs failed to

state a claim for which relief can be granted, pursuant to

Federal Rules of Civil Procedure 12(b) (2) and 12(b) (6).

Alternatively, the defendants move to transfer the action to the

United States District Court for the Eastern District of New

York, pursuant to 28 U.S.C. § 1404(a). Background1

Defendant NTD, a New York corporation located in Huntington

Station, New York, was founded in 1983. The parties dispute

whether NTD was founded independently by the defendant, James

Macri ("James"), or co-founded with his brother, the plaintiff,

Vincent Macri ("Vincent"). Since at least 1990, however, Vincent

and James equally owned and operated NTD, serving as officers and

directors. At that time, both James and Vincent were New York

residents with homes in Oyster Bay.

NTD engaged in the research and development of technologies

for prenatal screening tests for Down Syndrome and other

chromosomal abnormalities. The screening test method developed

by NTD is known as the "Free Beta" method. NTD consequently

developed computer apparatus and software technology for

implementing Free Beta tests. The software used for the Free

Beta tests is known as "ScreenLab." James, who has a doctorate

in medical sciences, is the inventor, and patents in his name

have been obtained or are pending on several NTD innovations.

Because of their inability to continue working together,

Vincent entered into a written agreement with James in May of

1 For the purposes of this motion only, the facts are taken from the plaintiffs' complaint and the affidavits and supporting materials submitted by the parties.

2 1993 to transfer his 50% of the NTD shares to James, giving him

100% ownership of NTD ("Master Agreement"). In exchange, Vincent

received 100% ownership of Equichem Research Institute, Ltd.

("Equichem NY"), which had been a wholly-owned subsidiary of NTD,

incorporated in New York. Under the terms of the Master

Agreement, Equichem NY would receive an exclusive royalty-free

license to sublicense, sell, or otherwise exploit ScreenLab. In

turn, Equichem NY issued to NTD a royalty-free right to use

ScreenLab internally. The Master Agreement provided that Vincent

would have the same right as NTD and/or James in the Free Beta

technology, and that James and NTD would render reasonable

assistance to Vincent and Equichem NY in obtaining patents for

ScreenLab. The Master Agreement further provided for bimonthly

payments to Vincent, commencing in June of 1993 and continuing

until May of 2003, with a decrease in the amount of the payments

taking effect after the first three years.

In June of 1993, the brothers executed five related

agreements to implement the Master Agreement. James executed a

Quitclaim Assignment that transferred to Equichem NY the entire

right, title and interest in the ScreenLab software and Down's

syndrome detection program developed by NTD as well as all rights

in American and European patents and patent applications for

ScreenLab technology. The parties entered into a License

3 Agreement that granted NTD and James a non-exclusive royalty-free

license to use, copy, reproduce, modify, improve, and enhance the

software assigned to Equichem NY. The License Agreement

expressly prohibits James and NTD from selling, licensing or

sublicensing, or otherwise exploiting the software. The Other

Products Agreement ("Products Agreement") grants to Equichem NY a

non-exclusive license to sublicense, sell, and otherwise exploit

other NTD technology products.2 Another agreement ("Free Beta

Agreement") provides that Vincent shall have the same legal and

equitable rights to use Free Beta Technology as James and NTD,

even though James is the developer and patent holder for the

technology. The Free Beta Agreement authorizes James to license

Free Beta technology to Eastman Kodak, with one-half of any

licensing payments to be paid to Vincent directly. Both James

and Vincent agreed to be bound by any such licensing agreement.

An additional agreement ("Consulting Agreement") provides that

Vincent will be available to NTD for consulting to the extent his

services do not impede his performance with Equichem NY. The

2 The Products Agreement refers to specific technology listed in "schedule 1" annexed to the agreement. The court did not find "schedule 1" among the materials submitted by the plaintiffs. The terms of the Products Agreement provide that NTD will make periodic payments to Equichem NY towards the marketing, research and commercialization of the schedule 1 products, and Equichem NY will pay royalties to NTD for licensing fees received from the schedule 1 products.

4 Consulting Agreement reiterates the compensation terms of the

Master Agreement, which states that Vincent will be paid $13,104

per month, for thirty-five months and $11,021 per month, for the

next eighty-four months, on a bimonthly basis.

The Master Agreement and related agreements were fully

negotiated and executed in the state of New York in May and June

of 1993. Only the Consulting Agreement, License Agreement, and

Products Agreement contain choice-of-law clauses, which state

that the agreements are to be governed by the laws of New York.

None of the agreements contains a forum selection clause.

At the time of the parties' agreements, NTD had been

negotiating with Eastman Kodak to license Free Beta technology

and ScreenLab software. In March of 1994, Kodak was granted an

exclusive license by NTD for Free Beta and a non-exclusive

license by Equichem NY for the use of ScreenLab. Kodak

subsequently sold its clinical laboratory business to Johnson &

Johnson, which assumed the licenses for Free Beta and ScreenLab.

In 1999, Johnson & Johnson's Free Beta license became non­

exclusive .

At some point in 1994, Vincent and his family moved to New

Hampshire. In 1995, Equichem Research Institute, Ltd. was

5 incorporated by Vincent in New Hampshire ("Equichem NH").3 The

plaintiffs characterize Equichem NH as the "successor" company to

Equichem NY. Although the defendants now dispute that

designation, the parties continued their business relationship

with James and NTD operating in New York, and Vincent and

Equichem NH operating in New Hampshire.

In April of 1996, James wrote Vincent to suggest changes to

the Consulting Agreement, for unspecified reasons.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
2002 DNH 089, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maori-v-maori-nhd-2002.